fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Nexstim, a medical device company, raises over EUR 11 million in new equity financing. Helsinki, Finland – January 26, 2011 – Nexstim Oy, a medical device company commercializing noninvasive brain diagnostic and therapy technologies, today announced that it has closed on additional equity financing of approximately EUR 11.4 million. The investment round was led by...
Russell G. Greig Appointed as Chairman of SyntaxinOxford, UK, 6th January 2011: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announced Dr Russell G. Greig, Ph. D., has been appointed as Chairman with immediate effect. In joining Syntaxin, Dr. Greig brings with him over 30 years experience in the pharmaceutical industry,...
DBV Technologies closes $25.5 (?19,4) million Series ‘C’ financing round including new investors InnoBio, Lundbeckfond Ventures, Shire plc, and ALTO Invest; as well as existing investors Sofinnova Partners and ALK AbelloProceeds will be used, for the most part, to further continue the clinical development of VIASKIN® Peanut, the world’s first epicutaneous skin patch for desensitization...
Lundbeckfond Ventures is LFÍ Life Science Investments new name
Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, announces it has successfully raised £18 million in new funding
Mette Kirstine Agger appointed Head of LFI Life Science Investments
1 46 47 48

Lundbeckfonden Ventures

Nyheder

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
4. februar 2019
BONESUPPORT and Lund University to present at Orthopaedic Research Society (ORS) 2019 Annual Meeting
1. februar 2019
scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX® On-Body Infusor
29. januar 2019